ArticleEngMedicine2025
Intraluminal MRI and interventions: Innovation and application.
Article in EngMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Intraluminal magnetic resonance imaging (MRI) is a promising option to guide interventions, offering several advantages over other imaging modalities. It provides high spatial and contrast resolution for imaging luminal structures, excellent extra-luminal soft tissue visualization, real-time tracking of interventional devices, and operates without ionizing radiation. The applications of intraluminal MRI range from high-resolution imaging of vessel walls to MRI-guided interventions for managing life-threatening conditions such as cardiovascular atherosclerotic disease and malignancies within luminal structures. Clinical use of intraluminal MR technology optimizes endovascular delivery of therapeutics to targeted vessel segments and guides myocardial delivery of stem cells. However, advancements are still required, such as the refinement of MR-compatible interventional devices, development of real-time "MR fluoroscopy" similar to X-ray fluoroscopy, and establishment of safe clinical environments with large bore and short magnets. These improvements are essential for broader clinical adoption of intraluminal MR technology in healthcare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.